The stock of Teva- Pharmaceutical Industries Ltd. ADR (TEVA) has seen a -6.67% decrease in the past week, with a -2.56% drop in the past month, and a 16.67% flourish in the past quarter. The volatility ratio for the week is 2.70%, and the volatility levels for the past 30 days are at 2.40% for TEVA. The simple moving average for the last 20 days is -4.12% for TEVA stock, with a simple moving average of 26.67% for the last 200 days.
Is It Worth Investing in Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) Right Now?
The stock has a 36-month beta value of 1.06. Opinions on the stock are mixed, with 3 analysts rating it as a “buy,” 1 as “overweight,” 17 as “hold,” and 5 as “sell.”
The public float for TEVA is 1.12B, and at present, short sellers hold a 1.03% of that float. On April 15, 2024, the average trading volume of TEVA was 10.47M shares.
TEVA) stock’s latest price update
The stock price of Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) has plunged by -4.11 when compared to previous closing price of 13.87, but the company has seen a -6.67% decline in its stock price over the last five trading sessions. Business Wire reported 2024-04-09 that TEL AVIV, Israel–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2024 financial results on Wednesday, May 8, 2024, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will b.
Analysts’ Opinion of TEVA
Many brokerage firms have already submitted their reports for TEVA stocks, with JP Morgan repeating the rating for TEVA by listing it as a “Neutral.” The predicted price for TEVA in the upcoming period, according to JP Morgan is $14 based on the research report published on March 08, 2024 of the current year 2024.
Piper Sandler, on the other hand, stated in their research note that they expect to see TEVA reach a price target of $19, previously predicting the price at $12. The rating they have provided for TEVA stocks is “Overweight” according to the report published on February 12th, 2024.
Jefferies gave a rating of “Buy” to TEVA, setting the target price at $14 in the report published on January 23rd of the current year.
TEVA Trading at -0.30% from the 50-Day Moving Average
After a stumble in the market that brought TEVA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -8.05% of loss for the given period.
Volatility was left at 2.40%, however, over the last 30 days, the volatility rate increased by 2.70%, as shares sank -1.48% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +9.92% upper at present.
During the last 5 trading sessions, TEVA fell by -6.67%, which changed the moving average for the period of 200-days by +74.08% in comparison to the 20-day moving average, which settled at $13.86. In addition, Teva- Pharmaceutical Industries Ltd. ADR saw 27.39% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TEVA starting from Kalif Eliyahu Sharon, who sale 77,550 shares at the price of $13.52 back on Mar 06 ’24. After this action, Kalif Eliyahu Sharon now owns 203,691 shares of Teva- Pharmaceutical Industries Ltd. ADR, valued at $1,048,119 using the latest closing price.
Sabag Mark, the EVP, International Markets of Teva- Pharmaceutical Industries Ltd. ADR, sale 100,000 shares at $13.52 during a trade that took place back on Mar 05 ’24, which means that Sabag Mark is holding 382,590 shares at $1,352,090 based on the most recent closing price.
Stock Fundamentals for TEVA
Current profitability levels for the company are sitting at:
- 0.06 for the present operating margin
- 0.48 for the gross margin
The net margin for Teva- Pharmaceutical Industries Ltd. ADR stands at -0.04. The total capital return value is set at 0.03. Equity return is now at value -6.84, with -1.20 for asset returns.
Based on Teva- Pharmaceutical Industries Ltd. ADR (TEVA), the company’s capital structure generated 0.73 points at debt to capital in total, while cash flow to debt ratio is standing at 0.07. The debt to equity ratio resting at 2.68. The interest coverage ratio of the stock is 0.91.
Currently, EBITDA for the company is 4.27 billion with net debt to EBITDA at 3.95. When we switch over and look at the enterprise to sales, we see a ratio of 2.01. The receivables turnover for the company is 4.65for trailing twelve months and the total asset turnover is 0.36. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.02.
Conclusion
To sum up, Teva- Pharmaceutical Industries Ltd. ADR (TEVA) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “sell” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
